Heska to Present at Upcoming Conferences in May & June 2018

LOVELAND, Colo., May 3, 2018 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; “Heska” or the “Company”), a provider of advanced veterinary diagnostic and specialty products, announced that Kevin Wilson, Heska’s President & Chief Executive Officer will be presenting at the following upcoming conferences in May and June 2018:

• May 21-22, 2018 - UBS Global Healthcare Conference at the Grand Hyatt, New York, NY. Mr. Wilson presents formally on May 22 at 1 p.m. ET and facilitates a breakout session at 1:30 p.m. ET. He will also be available for one-on-one meetings.
• May 23-24, 2018 - B. Riley & Co. 19^th Annual Institutional Investor Conference at the Loews Santa Monica Beach Hotel, Santa Monica, CA. Mr. Wilson will be presenting on May 23 at 2:30 p.m. PT and available on May 23rd for one-on-one meetings.
• May 30, 2018 - Stifel 2018 Dental & Veterinary Conference at the Peninsula Hotel, New York, NY. Mr. Wilson will be conducting a “Fireside Chat” and holding one-on-one meetings.
• June 5-8, 2018 - Jefferies Healthcare Conference at the Grand Hyatt, New York, NY. Mr. Wilson will be presenting on June 8 at 11:30 a.m. ET. He will also be available for one-on-one-meetings that day. The audio of the Company’s group presentation will be available at http://wsw.com/webcast/jeff113/hska/ and the webcast will be archived for 90 days following the live presentation.
• In addition, Heska will be conducting one-on-one meetings at Deutsche Bank’s 43^rd Annual Health Care Conference at the InterContinental Boston Hotel on May 8, 2018.

For more information regarding these conferences, please contact Brett Maas at Hayden IR.

About Heska

Heska Corporation (NASDAQ: HSKA) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products. Heska’s business is composed of Core Companion Animal Health (“CCA”) (81%) and Other Vaccines, Pharmaceuticals and Products (“OVP”) (19%). CCA includes, primarily for canine and feline use, point of care laboratory testing instruments and supplies under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP includes, primarily for herd animal health, private label vaccine and pharmaceutical production under third party agreements and channels. For further information on Heska and its products, visit www.heska.com.

CONTACT: Heska Corporation, Jon Aagaard, Director, Investor Relations, 970.619.3033, investorrelations@heska.com OR Hayden IR, Brett Maas, Managing Partner, 646.536.7331, brett@haydenir.com